Advertisement
MDchoice.com
We subscribe to the HONcode principles
of the Health On the Net Foundation


Health Information
Saturday, November 22, 2008
Find more information about this topic from either the Web or the world's best medical journals by using the search boxes at the top of this page.
 


Primary Immunodefiency Diseases

Discovering the Gene Defects That Cause Primary Immunodeficiency Diseases

In a series of truly remarkable discoveries, researchers have identified the gene defects that cause many primary immunodeficiency diseases including adenosine deaminase deficiency, purine nucleoside phosphorylase deficiency, X-linked severe combined immunodeficiency, MHC class II deficiency, CD3 deficiency, CD8 deficiency, X-linked agammaglobulinemia, X-linked hyper IgM syndrome, Wiskott-Aldrich syndrome, ataxia telangiectasia, chronic granulomatous disease, leukocyte adhesion deficiency, and many of the complement deficiencies.

Discovering the Role Gene Products Play in the Functioning of the Immune System. Once a defective gene has been identified, the role the gene product plays in the immune system can be evaluated. NIAID-supported investigators have identified the function of the product for some of the genes that cause primary immunodeficiency diseases. This information can be used to develop new therapies for immune system-mediated diseases.

Correcting the Gene Defect in Isolated Cells. As a first step toward gene therapy, NIAID-supported investigators as well as others have succeeded in transferring normal genes into cells taken from patients with primary immunodeficiency diseases and restoring immune function in these cells in the laboratory.

Correcting the Gene Defect in Patients. NIAID-supported researchers as well as others have begun to take stem cells (the cells that can generate all the cells of the immune system) from primary immunodeficiency disease patients, transfer normal genes into them, and give the cells back to the patient. Although these first efforts have resulted in the presence of only very small numbers of corrected cells in the blood of the patients, this is an important first step in demonstrating safety and feasibility.


Back | Contents | Next